Sana narrows focus to ex vivo cell therapies, lays off 29% of staff to reach key clinical data

Sana Biotech­nol­o­gy will let go about 29% of its staff, or rough­ly 120 em­ploy­ees, to fo­cus on its ex vi­vo cell ther­a­pies, ac­cord­ing to a source fa­mil­iar with the de­ci­sion.

The Seat­tle biotech said the cost-cut­ting, an­nounced af­ter Tues­day’s clos­ing bell, will help it con­serve cash so it can bankroll four cell ther­a­pies to clin­i­cal read­outs lat­er this year and in 2024. In Au­gust, End­points News re­port­ed that Sana had let go an undis­closed num­ber of em­ploy­ees in “a sin­gle area of re­search.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.